Loading
A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy is a phase 3 interventional study registered as NCT03767244 by Janssen Research & Development, LLC, with 2517 participants enrolled, started 2019-06-11 and due to reach its primary completion in 2026-12-01. Interventions recorded: Apalutamide, Androgen Deprivation Therapy (ADT) and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/